Legend Biotech names Ingrid Zhang CEO, effective September 15, 2026

Legend Biotech Corporation announced on September 15, 2026 that its Board of Directors appointed Ingrid Zhang as Chief Executive Officer, effective that same day. Zhang assumes the role from Alan Bash, who had served as interim CEO since July 2026 and will now resume his role as President of CARVYKTI.¹

Prior to joining Legend Biotech, Zhang most recently served as Chief Commercial Officer for Novartis International from June 2024 to August 2026.¹ Before that, she held several senior roles at Novartis, including President and Managing Director of Novartis China, President of China Innovative Medicines, and President of Novartis Pharmaceuticals China, dating back to 2011.¹ Earlier in her career she spent six years at AstraZeneca as Business Unit Head of Oncology and CNS, and held positions at Pfizer and McKinsey & Company.¹ She has also served on the board of Mettler-Toledo International Inc. since February 2023.¹

Under her employment agreement, Zhang's annual base salary is $950,000, with a discretionary annual bonus target of 90% of base salary.¹ She will also receive a restricted share unit grant with a fair market value target of at least $10 million on the effective date, plus a $150,000 signing bonus. If she is terminated for Cause or resigns without Good Reason within 12 months of the effective date, she must repay the signing bonus in full; if that occurs between 12 and 24 months, she must repay 50% of it.¹

Severance terms provide 12 months of base salary continuation if terminated without Cause or for Good Reason outside a Change in Control, rising to 24 months of base salary plus additional bonus and equity acceleration provisions if the termination occurs within 3 months before or 18 months after a Change in Control.¹